Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBausch Health Companies Inc

Bausch Health Companies Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
11.72 CAD 0.31 ( 2.72%)
Last update at 2026-11-04T20:41:00Z
VOLUME
388593
Market Cap
2924.22M
P/E
13.98

Momentum Score

…

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
11.50
Low
11.81
High
52 Week Price Range
6.06
Low
11.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bausch Health Companies Inc is a diversified specialty pharmaceutical and eye-health company that owns the Bausch + Lomb consumer and prescription portfolio. Long-term growth drivers include aging-related demand for eye care, portfolio optimization and cost reductions, and successful execution of strategic restructuring, which may benefit margins and cash flow while enabling reinvestment.

Key risks include elevated leverage and debt servicing requirements, legal and regulatory exposure, pricing and competitive pressure in core markets, and execution risk around product lifecycles and integration.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.41
Dividend Yield
-
Revenue TTM
10266.00M
Revenue Per Share
27.68
Gross Profit TTM
7253.00M
Debt / Equity
-38.35
ROE
43.64%
Net Debt
19884.75M
ROCE
10.04%
Diluted EPS TTM
0.56

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 373.42M 167.00M -390.00M -129.00M -1024.00M
Minority interest 37.00M 26.00M 19.00M -13.00M -11.00M
Net income 159.75M -46.00M -592.00M -212.00M -937.00M
Selling general administrative 3438.00M 2497.00M 2270.00M 2625.00M 2624.00M
Selling and marketing expenses - 786.00M 625.00M - -
Gross profit 6361.44M 6843.00M 6198.00M 5760.00M 6040.00M
Reconciled depreciation 1208.00M 1267.00M 1264.00M 1394.00M 1375.00M
Ebit 2223.25M 1555.00M 938.00M 1370.00M 1210.00M
Ebitda 3452.40M 2822.00M 2202.00M 2585.00M 2585.00M
Depreciation and amortization 1229.15M 1267.00M 1264.00M 1215.00M 1375.00M
Operating income 2223.25M 1546.00M 963.00M 1370.00M 1210.00M
Other operating expenses 8222.46M 8079.00M 7794.00M 6768.00M 7231.00M
Interest expense 1642.25M 1388.00M 1328.00M 1464.00M 1426.00M
Tax provision 247.00M 239.00M 221.00M 83.00M -87.00M
Interest income 1608.00M 1402.00M 26.00M 1458.00M 1412.00M
Net interest income -1556.00M -1355.00M -1302.00M -1450.00M -1419.00M
Income tax expense 251.32M 239.00M 221.00M 83.00M -87.00M
Total revenue 10445.71M 9625.00M 8757.00M 8124.00M 8434.00M
Total operating expenses 4138.20M 5297.00M 5235.00M 4404.00M 4837.00M
Cost of revenue 4084.27M 2782.00M 2559.00M 2364.00M 2394.00M
Total other income expense net -1849.83M -1379.00M -1353.00M -1499.00M -2234.00M
Net income from continuing ops 120.00M -72.00M -611.00M -212.00M -937.00M
Net income applicable to common shares 157.00M -46.00M -592.00M -225.00M -948.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 26318.02M 26523.00M 27350.00M 25686.00M 29202.00M
Intangible assets 4634.55M 5551.00M 6456.00M 5800.00M 6948.00M
Other current assets 850.45M 838.00M 1092.00M 776.00M 720.00M
Total liab 25941.70M 26845.00M 27432.00M 25426.00M 29236.00M
Total stockholder equity -552.99M -1279.00M -1022.00M -692.00M -106.00M
Other current liab 3277.03M 1037.00M 1041.00M 2988.00M 4791.00M
Common stock 10496.86M - 10423.00M 10391.00M 10317.00M
Capital stock 10516.00M 10490.00M 10423.00M 10391.00M 10317.00M
Retained earnings -9649.41M -9824.00M -9778.00M -9186.00M -8961.00M
Other liab - - - 967.00M 1170.00M
Good will 11250.49M 11087.00M 11183.00M 11547.00M 12457.00M
Other assets 2006.00M - - 2271.00M 2345.00M
Cash 1322.59M 1181.00M 947.00M 564.00M 582.00M
Cash and equivalents 1309.00M - - 564.00M 582.00M
Total current liabilities 4172.39M 6752.00M 4302.00M 3941.00M 5198.00M
Current deferred revenue - - 2092.00M - -
Net debt 19884.75M 20435.00M 21441.00M 20202.00M 22072.00M
Short term debt 296.46M - 450.00M 432.00M 0.00M
Short long term debt 225.00M 2674.00M 450.00M 432.00M -
Short long term debt total 21207.34M - 22388.00M 20766.00M 22654.00M
Other stockholder equity 356.35M - 214.00M 159.00M 462.00M
Property plant equipment 2289.00M - - 1821.00M 1845.00M
Total current assets 6145.80M 5774.00M 5596.00M 4247.00M 5607.00M
Net tangible assets - - - -18039.00M -19511.00M
Net receivables 2346.72M 2140.00M 1998.00M 1790.00M 1775.00M
Long term debt 20592.00M 18942.00M 21938.00M 20334.00M 22654.00M
Inventory 1626.04M 1595.00M 1544.00M 1090.00M 993.00M
Accounts payable 598.91M 656.00M 719.00M 521.00M 407.00M
Accumulated other comprehensive income -1756.80M - -1881.00M -2056.00M -1924.00M
Non currrent assets other 377.31M 363.00M 307.00M 326.00M 340.00M
Non current assets total 20172.22M 20749.00M 21754.00M 21439.00M 23595.00M
Capital lease obligations 34.00M - - - -
Long term debt total 20615.00M - - 20334.00M 22654.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3.00M -454.00M -2133.00M -303.00M -4.00M
Change to liabilities - - - -75.00M 121.00M
Total cashflows from investing activities -605.42M -454.00M -2145.00M -303.00M 409.00M
Net borrowings -637.00M -799.00M 1581.00M -1010.00M -1340.00M
Total cash from financing activities -709.20M -868.00M 1475.00M -474.00M -1513.00M
Change to operating activities - - - -66.00M -4.00M
Net income 159.75M -72.00M -611.00M -212.00M -937.00M
Change in cash 64.78M 239.00M 371.00M -1528.00M 303.00M
Begin period cash flow 1257.80M 962.00M 591.00M 2119.00M 1816.00M
End period cash flow 1322.59M 1201.00M 962.00M 591.00M 2119.00M
Total cash from operating activities 1378.72M 1597.00M 1032.00M -728.00M 1426.00M
Issuance of capital stock - 0.00M 0.00M 675.00M -
Depreciation 1229.15M 1267.00M 1264.00M 1394.00M 1552.00M
Other cashflows from investing activities 12.21M 17.00M -39.00M -35.00M 27.00M
Change to inventory -12.21M -267.00M -322.00M -198.00M -16.00M
Change to account receivables -136.35M -216.00M -195.00M -57.00M -229.00M
Sale purchase of stock - -26.00M -24.00M 675.00M -
Other cashflows from financing activities -61.05M -43.00M -82.00M 6697.00M 1927.00M
Change to netincome - - - -1600.00M 895.00M
Capital expenditures 403.95M 340.00M 272.00M 268.00M 283.00M
Change in working capital -222.83M 7.00M -582.00M -396.00M -128.00M
Stock based compensation 216.00M 150.00M 132.00M 126.00M 128.00M
Other non cash items 131.26M 179.00M 778.00M -1464.00M 1036.00M
Free cash flow 974.77M 1257.00M 760.00M -996.00M 1143.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BHC
Bausch Health Companies Inc		 0.31
2.72%		 11.72 13.98 1.35 0.28 18.74 2.12 6.84
CURA
Curaleaf Holdings Inc.		 -0.74
5.20%		 13.49 - 138.89 2.57 3.14 2.47 13.10
CRON
Cronos Group Inc		 0.16
3.36%		 4.92 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.41
11.02%		 4.13 - 1000.00 1.28 0.53 1.08 -2.30
GUD
Knight Therapeutics Inc.		 0.02
0.18%		 11.28 - 48.54 1.64 0.96 1.60 11.97

Profile*

Bausch Health Companies Inc

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8

514 744 6792

https://www.bauschhealth.com

20300

Name Title Year Born
Mr. Thomas J. Appio CEO & Director 1962
Mr. Thomas G. Vadaketh Exec. VP & CFO 1963
Mr. Mirza Dautbegovic Sr. VP & COO NA
Mr. John S. Barresi Sr. VP, Controller & Chief Accounting Officer 1973
Dr. Robert F. Butz VP of Medical & Scientific Affairs NA
Mr. Arthur J. Shannon Sr. VP and Head of Investor Relations & Global Communications NA
Ms. Seana Carson Exec. VP & Gen. Counsel 1972
Ms. Kathleen Fitzpatrick Sr. VP & Chief HR Officer NA
Dr. Tage Ramakrishna M.D. Chief Medical Officer and Pres of R&D 1974
Mr. Jeff Hartness Sr. VP of Market Access, Commercial Operations & Gov. Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…